Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent Director Patrick Fernet was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Mar 05
KDA Group Inc., Annual General Meeting, Apr 29, 2026 KDA Group Inc., Annual General Meeting, Apr 29, 2026. Location: quebec, quebec city Canada Announcement • May 30
KDA Group Inc. announced that it has received CAD 2.2 million in funding KDA Group Inc announced a private placement to issue 8,800,000 units at a price of CAD 0.25 per Unit for total gross proceeds of CAD 2,200,000 on May 29, 2025. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.35 per Common share for a period of 24 months ending May 29, 2027. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on September 30, 2025 in accordance with applicable securities regulations. The transaction included participation from accredited investors. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Insider, Marc Lemieux purchased 80,000 Units for a total consideration of CAD 20,000. Marc Lemieux is hereinafter referred to as the “Insider”. No finder’s fee nor commission are payable in connection with the Private Placement. Announcement • May 22
KDA Group Inc. Receives DSQ Certification for Adherize+ Platform KDA Group Inc. announced that its Adherize+ platform, designed to optimize patient follow-up and care coordination, has officially received certification from Dossier Sante Quebec ("DSQ"). This authorization marks a major step toward full production deployment. At the core of Adherize+ is Medherize, a high-impact specialized module developed to support interdisciplinary follow-up for patients undergoing targeted cancer therapies. Leveraging structured, real-time data exchange through granular integration, a first in Quebec, Medherize brings significant value to healthcare operations and outcomes, positioning it as a key strategic asset within the Adherize+ ecosystem for the entire Quebec population. With this certification secured, the pilot project at Hopital Saint-Sacrement in Quebec City is set to begin, marking the start of a phased rollout to other healthcare institutions across the province. As more specialty therapies are delivered orally and managed outside of hospitals by community pharmacies, the need for robust digital tools like Medherize are becoming essential for physicians, pharmacists, and nursing staff. These high-cost treatments are often associated with significant adverse effects and adherence challenges. Ensuring appropriate monitoring can directly impact patient survival and reduce systemic risks. Medherize is designed to meet this growing need, improving continuity of care for patients whose lives depend on strict therapeutic management. Announcement • Apr 16
KDA Group Inc. Reaches Final Certification Phase for Medherize with Dossier Sante Quebec KDA Group Inc. announced that it has reached the final phase in the certification process for its Medherize platform's integration with the Dossier Sante Quebec ("DSQ"). Following the successful completion of the initial certification phase announced on December 3, 2024, all three required development phases for the module have now been completed. On April 7, 2025, the Direction des produces de prestations de services du DSQ, through its Integration and Certification Support Team, confirmed that the final self-assessment phase was successfully passed. The final audit is scheduled for April 22-24, 2025, marking the last technical validation before full integration. The initial deployment of Medherize is planned for May 5, 2025, at the St-Sacrement Hospital Center in Quebec City, followed by a progressive rollout across other healthcare institutions in the province. KDA is now the first technology provider in Quebec to successfully certify for DSQ integration using the granular data mode--a major advancement in the transmission of clinical information. Unlike laboratory results delivered in PDF format, which are often static and difficult to process, the granular mode enables structured, interoperable, and seamlessly integrable data within clinical systems. This model provides substantial gains in efficiency, safety, quality of care, as well as reductions in delays and human error. Announcement • Feb 25
KDA Group Inc. Approves the Appointment of Jean-Marc Léveillé as Members of the Audit Committee KDA Group Inc. at its annual general meeting of shareholders held on February 20, 2025 approved the appointment of Jean-Marc Léveillé as members of the Corporation's audit committee. Reported Earnings • Dec 30
First quarter 2025 earnings released: CA$0.014 loss per share (vs CA$0.01 loss in 1Q 2024) First quarter 2025 results: CA$0.014 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Net loss: CA$2.20m (loss widened 46% from 1Q 2024). Board Change • Dec 30
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Patrick Fernet was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 24
KDA Group Inc., Annual General Meeting, Feb 20, 2025 KDA Group Inc., Annual General Meeting, Feb 20, 2025. Location: quebec, quebec Canada New Risk • Jun 23
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (CA$204k revenue, or US$149k). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€35.3m market cap, or US$37.8m). Announcement • Jun 13
KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast Cancer KDA Group Inc. announced the launch of Medherize, its revolutionary new platform dedicated to the clinical management of patients requiring specialized medications. This pioneering project particularly focuses on CDK 4/6 inhibitors used in the treatment of breast cancer, with the objective of ensuring optimal and personalized patient follow-up. Medherize marks the first collaboration among specialist doctors, pharmacists and patients to offer integrated and coordinated care. KDA's new clinical management solution is designed to address the complex challenges associated with the administration of CDK 4/6 inhibitors, essential medications in the treatment of certain types of breast cancer. This innovative technology offers an integrated platform enabling healthcare professionals to accurately monitor patient treatments, track side effects and adjust doses in real-time while ensuring seamless communication between patients and care providers. Key Features of Medherize: Personalized Patient Follow-Up: An intuitive user interface allowing doctors to personalize and track treatment plans for each patient, ensuring better adherence to prescribed therapies. Real-Time Monitoring: Integration of monitoring devices that collect real-time data on patients' health status, enabling rapid intervention when needed. Side Effect Management: A proactive notification system to monitor and manage potential side effects of CDK 4/6 inhibitor. Optimized Communication: A secure communication platform facilitating exchanges between patients, doctors and pharmacists, thereby enhancing care coordination. Analysis and Reporting. Advanced analytical tools to generate detailed reports on treatment effectiveness, supporting evidence-based clinical decision-making. This pilot project, the first of its kind, will be deployed in the Corporation's partner clinics and hospitals in the coming months, with ambitions to expand internationally. KDA remains committed to investing in innovation and closely collaborating with healthcare professionals to continue developing cutting-edge solutions that meet the evolving needs of the healthcare sector. Artificial intelligence and new technologies could reduce healthcare spending by $200 to $360 billion. Announcement • Mar 16
KDA Group Inc., Annual General Meeting, May 16, 2024 KDA Group Inc., Annual General Meeting, May 16, 2024. Announcement • Dec 09
KDA Group Inc. announced that it has received CAD 1.125 million in funding KDA Group Inc. announced a private placement to issue 11,250,000 units at an issue price of CAD 0.10 per unit for the gross proceeds of CAD 1.250,000 on December 8, 2023. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.15 per Common share for a period of 24 months ending December 8, 2025. The transaction included participation from accredited investors. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on April 9, 2024 in accordance with applicable securities regulations. No finder’s fee nor commission are payable in connection with the Private Placement. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Reported Earnings • Dec 01
Full year 2023 earnings released: EPS: CA$0.004 (vs CA$0.031 loss in FY 2022) Full year 2023 results: EPS: CA$0.004 (up from CA$0.031 loss in FY 2022). Net income: CA$618.4k (up CA$5.18m from FY 2022). Board Change • Sep 22
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 4 highly experienced directors. 1 independent director (3 non-independent directors). Co-Founder, Executive VP & Director Isabelle Begin is the most experienced director on the board, commencing their role in 2015. Independent Director Patrick Fernet was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Jun 29
KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million. KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million on June 27, 2023. The consideration will be paid through the issuance of 10,000,000 Class A shares in the share capital of KDA Group. ZoomMed Board of Directors has unanimously approved an agreement for the sale. The transaction will be completed following the satisfaction or waiver of all closing conditions provided for in the asset purchase agreement, including the approval by the shareholders of the ZoomMed and obtaining the approvals from applicable regulatory authorities. 